Amgen Inc. $AMGN Shares Purchased by Moors & Cabot Inc.

Moors & Cabot Inc. grew its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 23.5% during the 3rd quarter, Holdings Channel reports. The firm owned 18,382 shares of the medical research company’s stock after purchasing an additional 3,498 shares during the period. Moors & Cabot Inc.’s holdings in Amgen were worth $7,748,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of AMGN. Quest 10 Wealth Builders Inc. boosted its stake in Amgen by 220.0% during the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after buying an additional 55 shares in the last quarter. Wellington Altus USA Inc. grew its holdings in Amgen by 72.3% during the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after acquiring an additional 34 shares during the period. Nvwm LLC raised its position in Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after acquiring an additional 66 shares in the last quarter. PFS Partners LLC raised its position in Amgen by 95.5% in the third quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after acquiring an additional 42 shares in the last quarter. Finally, TOWER TRUST & INVESTMENT Co acquired a new stake in Amgen in the 3rd quarter valued at about $38,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN opened at $465.67 on Monday. The company has a 50-day moving average of $425.31 and a two-hundred day moving average of $381.17. The stock has a market cap of $251.89 billion, a price-to-earnings ratio of 27.01, a PEG ratio of 3.24 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.64 earnings per share. On average, equities research analysts expect that Amgen Inc. will post 23.37 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s payout ratio is presently 58.47%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Bank of America raised their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $410.00 price objective on shares of Amgen in a research note on Wednesday, September 23rd. Weiss Ratings upgraded shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. Oppenheimer reissued an “outperform” rating on shares of Amgen in a research note on Friday, October 23rd. Finally, TD Cowen raised their target price on shares of Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $424.66.

Get Our Latest Research Report on AMGN

About Amgen

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.